SLC2A1 and prostate cancer: Treatment of AR-positive LNCaP prostate cancer cells with the synthetic steroid R1881 induced transcriptional upregulation of glucose transporters (GLUT1, GLUT12) and glycolytic enzymes (HK1/2, and PFKB2), increased glucose uptake, glucose entry into glycolysis, and glucose storage into lipids (de novo lipogenesis) (25–27).